Dublin, Sept. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Biopharmaceuticals Contract Manufacturing Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global biopharmaceuticals contract manufacturing market size is expected to reach USD 25.1 billion by 2028 registering a CAGR of 5.7%.
Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the company demands with respect to regulatory standards and new services.
The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise over the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio.
The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to the Covid-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the global market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's Covid-19 vaccine candidate, AZD1222.
The future growth of CMOs is highly dependent on the promising opportunities offered by the biopharmaceutical industry, the bioprocessing industry, and the contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the marke
For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which they shall utilize along with their outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Biopharmaceuticals Contract Manufacturing Market Report Highlights
Mammalian-based biopharmaceutical contract manufacturing captured the largest market share of over 59% in 2020 owing to the high penetration of mammalian expression system for biologics development
Out of all the services offered in this market, process development contributed to the largest share in 2020 owing to high capital investment, especially in the downstream process
The complexities associated with regulatory approval and good manufacturing practice pronounces the demand for the established contract manufacturers to ensure compliance with regulatory standards
The biologics contract manufacturing segment dominated the global market in 2020 owing to higher demand for biologics production
However, the biosimilar segment is estimated to register the fastest CAGR from 2021 to 2028 due to cost-saving advantages associated with biosimilars development
North America was the dominant regional market in 2020 due to the presence of an effective regulatory framework for biologics development in the U.S.
However, Asia Pacific is expected to emerge as the fastest-growing regional market from 2021 to 2028 owing to emerging countries, such as India and China, incorporating developments to sustain the competition
Several international companies are seeking outsourcing of biopharmaceutical production to Asian countries owing to the continuous expansion of Asian CMOs that offer services at a less price, as compared to the service providers based in western countries
Market Segmentation & Scope
Market driver analysis
Rise in investment by CMOs for capacity expansion
Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
Notable growth of biologics
Robust biopharmaceuticals pipeline
Cost and time saving benefits offered by contract services
Market restraint analysis
Limited outsourcing amongst well-established biopharmaceutical manufacturer
Expansion of fill-and-finish CMOs
Emergence of single-use bioprocessing equipment & solutions
Funding & investments
Merger & acquisitions in CMO industry
Trading of CMOs at strong EV/EBITDA multiples
Current trends in biopharmaceutical industry
Distribution of products & projects in development stage by clinical phase
Key finding of the analysis:
Pipeline analysis for biosimilar drugs, as of February 2018
Total global biopharmaceutical R&D spending
Number of drugs in clinical development phase, 2015
Pricing Analysis for Process Development
Cell line/expression system pricing
Operating and construction cost advantage due to single-use bioprocessing equipment
Bioprocessing operating cost items and ranges
Bioprocessing pricing analysis based on product type
Downstream bioprocessing pricing analysis
Cost analyses for buffer purchasing
Customer Relationship Management in Contract Manufacturing
Selection process of CMO
Operations and quality oversight of CMOs
Boehringer Ingelheim GmbH
Inno Biologics Sdn Bhd
Rentschler Biotechnologie GmbH
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
TOYOBO CO., LTD.
Thermo Fisher Scientific, Inc.
Binex Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/66urts
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900